Brent Saunders Acquires Shares in ARS Pharmaceuticals
Brent Saunders bought 30,000 shares of ARS Pharmaceuticals on June 24, 2026.
Key Points
- Brent Saunders purchased 30,000 shares of ARS Pharmaceuticals on June 24, 2026, as part of an insider buy.
- ARS Pharmaceuticals, trading on NasdaqGM under SPRY, had a market cap of $848 million and a 52-week range of $6.66 to $18.90.
- Analysts maintain a strong buy consensus for ARS Pharmaceuticals with a mean price target of $28.40.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Brent Saunders, a notable insider, purchased 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026. The transaction was not part of a pre-planned trading program.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
On June 24, 2026, several insiders, including Brent Saunders, acquired shares of ARS Pharmaceuticals. Each insider bought 30,000 shares. These transactions were not conducted under Rule 10b5-1 plans, indicating they were not pre-scheduled.
Other Institutional Activity in ARS Pharmaceuticals
Several institutional investors have been active in ARS Pharmaceuticals. Rubric Capital Management LP increased its holdings by 1.8 million shares, ending with 8 million shares valued at about $64.2 million, marking a 29% increase. Millennium Management LLC boosted its stake by 2.8 million shares to 5.98 million shares, worth approximately $48 million, an 88.8% increase. In contrast, BlackRock, Inc. slightly reduced its position by 73,063 shares, holding a total of 5.01 million shares valued at $40.2 million, a 1.4% decrease.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
Shares of ARS Pharmaceuticals traded near $8.54 on Saturday. The company, with a market cap of $848 million, operates in the biotechnology sector. Its stock has a 52-week low of $6.66 and a high of $18.90. The 50-day moving average is $8.70, while the 200-day moving average is $9.36. The company has a current ratio of 4.94, a quick ratio of 4.65, and a debt-to-equity ratio of 279.24. ARS Pharmaceuticals is not currently profitable, hence it has no meaningful forward P/E ratio.
$SPRY stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
ARS Pharmaceuticals reported revenue of $98.99 million, with a revenue growth rate of 1.85%. The company has a net margin of -200% and a return on equity of -136.4%. The next earnings report is expected on August 13, 2026.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its buy rating on ARS Pharmaceuticals with a price target of $24. Cantor Fitzgerald also maintained a buy rating on May 28, 2026, with a target of $30. The consensus among five analysts is a strong buy, with a mean price target of $28.40.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California. Founded in 2015, it focuses on developing treatments for severe allergic reactions. Its flagship product, neffy, offers a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. The company employs 154 people and is led by CEO Richard E. Lowenthal.
Bottom Line
Brent Saunders' recent purchase of ARS Pharmaceuticals shares highlights insider confidence in the company. With its innovative approach to treating severe allergic reactions, ARS Pharmaceuticals is a company to watch. Analysts' strong buy ratings further underscore interest in its potential, though it's important to remember that insider transactions are just one factor in evaluating a stock's future prospects.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.